Aytu BioPharma, Inc. (AYTU)

Aytu BioPharma Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Year	2023	2022	2021	2020	2019
Net Income	-17.05	-108.78	-58.29	-13.62	-27.13
Depreciation & Amortization	8.82	10.15	9.2	5.71	2.73
Share-Based Compensation	6.05	5.25	3.57	1.08	1.03
Other Operating Activities	-2.94	64.56	19.55	-21.55	9.54
Operating Cash Flow	-5.13	-28.82	-25.96	-28.37	-13.83
Capital Expenditures	0	0	0	0	-0.06
Acquisitions	-0.01	-3.18	-2.82	-5.66	-1.01
Other Investing Activities	-0.11	-0.07	0.04	0.01	0
Investing Cash Flow	-0.12	-3.25	-2.78	-5.66	-1.06
Share Issuance / Repurchase	15.58	11.69	40.15	60.33	13.7
Debt Issued / Paid	-6.7	-10.16	-9.83	-16.25	5
Other Financing Activities	-	-0.01	-0.01	26.99	0.38
Financing Cash Flow	8.87	1.53	30.31	71.07	19.08
Net Cash Flow	3.63	-30.54	1.57	37.04	4.18
Free Cash Flow	-5.13	-28.82	-25.96	-28.37	-13.89
Free Cash Flow Margin	-4.78%	-29.82%	-39.56%	-102.69%	-189.76%
Free Cash Flow Per Share	-1.54	-19.61	-31.01	-125.57	-356.44

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).